Evidence map›Paper›PMID 25770175›Full record

Observational studyClinical journal of the American Society of Nephrology : CJASN2015

Vascular calcification in patients with nondialysis CKD over 3 years.

José L Górriz, Pablo Molina, M Jesús Cerverón, Rocío Vila, Jordi Bover, Javier Nieto, Guillermina Barril, Alberto Martínez-Castelao, Elvira Fernández, Verónica Escudero and 7 more

Open access · greenAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Clinical journal of the American Society of Nephrology : CJASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 2 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 2 syntheses or guidelines pooled it, 185 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Deoxycholic Acid, a Metabolite of Circulating Bile Acids, and Coronary Artery Vascular Calcification in CKD.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2018
    Trial
  4. Trial
  5. Article
  6. Observational
  7. Article
  8. Review
  9. Review
  10. The international journal of cardiovascular imaging · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

José L GórrizDue to the number of contributing authors, the affiliations are provided in the Supplemental Material. jlgorriz@senefro.org.
Pablo MolinaDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
M Jesús CerverónDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Rocío VilaDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Jordi BoverDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Javier NietoDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Guillermina BarrilDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Alberto Martínez-CastelaoDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Elvira FernándezDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Verónica EscuderoDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Celestino PiñeraDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Teresa AdragaoDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Juan F Navarro-GonzalezDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Luis M MolineroDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Cristina Castro-AlonsoDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Luis M PallardóDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Sophie A JamalDue to the number of contributing authors, the affiliations are provided in the Supplemental Material.
Hospital Universitario Doctor Peset · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesVascular calcification (VC) is common in CKD, but little is known about its prognostic effect on patients with nondialysis CKD. The prevalence of VC and its ability to predict death, time to hospitalization, and renal progression were assessed. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Study of Mineral and Bone Disorders in CKD in Spain is a prospective, observational, 3-year follow-up study of 742 patients with nondialysis CKD stages 3-5 from 39 centers in Spain from April to May 2009. VC was assessed using Adragao (AS; x-ray pelvis and hands) and Kauppila (KS; x-ray lateral lumbar spine) scores from 572 and 568 patients, respectively. The primary end point was death. Secondary outcomes were hospital admissions and appearance of a combined renal end point (beginning of dialysis or drop >30% in eGFR). Factors related to VC were assessed by logistic regression analysis. Survival analysis was assessed by Cox proportional models.

resultsVC was present in 79% of patients and prominent in 47% (AS≥3 or KS>6). Age (odds ratio [OR], 1.05; 95% confidence interval [95% CI], 1.02 to 1.07; P<0.001), phosphorous (OR, 1.68; 95% CI, 1.28 to 2.20; P<0.001), and diabetes (OR, 2.11; 95% CI, 1.32 to 3.35; P=0.002) were independently related to AS≥3. After a median follow-up of 35 months (interquartile range=17-36), there were 70 deaths (10%). After multivariate adjustment for age, smoking, diabetes, comorbidity, renal function, and level of phosphorous, AS≥3 but not KS>6 was independently associated with all-cause (hazard ratio [HR], 2.07; 95% CI, 1.07 to 4.01; P=0.03) and cardiovascular (HR, 3.46; 95% CI, 1.27 to 9.45; P=0.02) mortality as well as a shorter hospitalization event-free period (HR, 1.14; 95% CI, 1.06 to 1.22; P<0.001). VC did not predict renal progression.

conclusionsVC is highly prevalent in patients with CKD. VC assessment using AS independently predicts death and time to hospitalization. Therefore, it could be a useful index to identify patients with CKD at high risk of death and morbidity as previously reported in patients on dialysis.

Indexed as

AgedChi-Square DistributionDisease-Free SurvivalDisease ProgressionFemaleGlomerular Filtration RateHospitalizationHumansKaplan-Meier EstimateKidneyLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioPredictive Value of Testscardiovascular diseasechronic renal diseasemetabolismmineralvascular calcification

Identifiers

PMID25770175
PMCPMC4386255
OpenAlexW2055599709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.